Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies

Area of Science:

• Oncology
• Pathology
• Genomics

Background:

• Early breast cancer (BC) requires precise risk stratification for effective clinical management.
• Current guidelines for risk stratification in early BC are often insufficient.
• Histopathological features and biomarkers are crucial for predicting patient outcomes.

Purpose of the Study:

• To provide a comprehensive overview of current early breast cancer risk stratification strategies.
• To serve as a practical guide for histopathologists and molecular pathologists.
• To highlight the need for standardized methodologies and integrated pathological models.

Main Methods:

• Review of traditional histopathological criteria (tumor size, grade, lymph node status, etc.).
• Assessment of key biomarkers including hormone receptors, HER2, and BRCA1/2.
• Exploration of molecular subtyping via gene expression profiling and "omics" technologies (tissue and liquid biopsy).

Main Results:

• Traditional histological factors remain significant prognostic indicators.
• Molecular subtyping offers valuable insights for personalized treatment decisions.
• "Omics" technologies expand the capabilities for risk assessment in early BC.

Conclusions:

• Standardized methodologies are needed for integrated pathological models in early BC risk stratification.
• Combining histological, biomarker, and molecular data is essential for comprehensive risk assessment.
• This review aims to enhance clinical decision-making for early breast cancer patients.